


Growing pipeline across three therapeutic areas



Oncology



Rare Disease



Neuroscience

Information shown as of February 2026

R²: Lenalidomide + Rituximab; EZH2: Enhancer of zeste homolog 2; 2L: Second Line; FL: Follicular Lymphoma; :RAF Rapidly Accelerated Fibrosarcoma; 1L: First line; pLGG: Pediatric Low-Grade Glioma; BTN3A: Butyrophilin-3A; AML: Acute Myeloid Leukemia; ERKi: ERK inhibitor of the MAPK pathway; RAfi: RAF inhibitor of the MAPK pathway; ADC: Antibody-drug conjugate; TCA: T-cell activator; IBAT: Ileal Bile Acid Transporter; BA: Biliary Atresia; PPAR: Peroxisome Proliferator-Activated Receptor; PBC: Primary Biliary Cholangitis; PSC: Primary Sclerosing Cholangitis; BoNTA: Botulinum Toxin Serotype A; GL: Glabellar Lines; FHL: Forehead Lines; LCL: Lateral Canthal Lines; AUL: Adult Upper Limb Spasticity; Ax: Aesthetics; Tx: Therapeutics; ¹ Executed by Day One Biopharmaceuticals

Disclaimer: trials are event-driven & timings can change